TargetMol

AKOS B018304

Product Code:
 
TAR-T5103
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5103-1mg1mg£165.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-2mg2mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-5mg5mg£304.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-1mL1 mL * 10 mM (in DMSO)£327.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-10mg10mg£438.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-25mg25mg£675.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-50mg50mg£922.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5103-100mg100mg£1,219.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AKOS B018304 is an arylalkylidene derivative with polar substitution at para-position.
CAS:
6308-22-1
Formula:
C10H6N2O3S2
Molecular Weight:
266.3
Purity:
0.9919
SMILES:
[O-][N+](=O)c1ccccc1C=C1SC(=S)NC1=O

References

Jadav SS, et al. Thiazolidone derivatives as inhibitors of chikungunya virus. Eur J Med Chem. 2015 Jan 7;89:172-8.